These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15333965)

  • 1. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought.
    Adams LA; Lindor KD
    Indian J Gastroenterol; 2004; 23(4):127-8. PubMed ID: 15333965
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.
    Hatzitolios A; Savopoulos C; Lazaraki G; Sidiropoulos I; Haritanti P; Lefkopoulos A; Karagiannopoulou G; Tzioufa V; Dimitrios K
    Indian J Gastroenterol; 2004; 23(4):131-4. PubMed ID: 15333967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
    Arendt BM; Allard JP
    Am J Gastroenterol; 2011 Jan; 106(1):78-80. PubMed ID: 21212755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
    Foster T; Budoff MJ; Saab S; Ahmadi N; Gordon C; Guerci AD
    Am J Gastroenterol; 2011 Jan; 106(1):71-7. PubMed ID: 20842109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.
    Matafome P; Nunes E; Louro T; Amaral C; Crisóstomo J; Rodrigues L; Moedas AR; Monteiro P; Cipriano A; Seiça R
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Mar; 379(3):241-51. PubMed ID: 18936912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
    Indian Heart J; 2001; 53(2):237. PubMed ID: 11428488
    [No Abstract]   [Full Text] [Related]  

  • 8. [The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia].
    Nikitina NM; Rebrov AP
    Kardiologiia; 2009; 49(9):21-6. PubMed ID: 19772499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).
    Hussein O; Grosovski M; Schlesinger S; Szvalb S; Assy N
    Dig Dis Sci; 2007 Oct; 52(10):2512-9. PubMed ID: 17404856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
    Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
    Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
    Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical management of primary nonalcoholic fatty liver disease].
    Moreno Sánchez D
    Med Clin (Barc); 2005 Jun; 125(3):108-16. PubMed ID: 15989845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
    Wierzbicki AS; Reynolds TM; Crook MA
    Am J Cardiol; 2002 Jan; 89(2):229-31. PubMed ID: 11792350
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
    Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
    Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia].
    Musto D; Martorelli L; Russo M; Esposito G; Amato MR; Esposito P; Riegler G
    Minerva Gastroenterol Dietol; 2010 Dec; 56(4):389-95. PubMed ID: 21139538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
    Koksal M; Eren MA; Turan MN; Sabuncu T
    Eur J Intern Med; 2011 Jun; 22(3):249-53. PubMed ID: 21570643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
    Lampl Y; Lorberboym M; Gilad R; Vysberg I; Tikozky A; Sadeh M; Boaz M
    Clin Neuropharmacol; 2010 May; 33(3):129-34. PubMed ID: 20502132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
    Uzun M; Yiğiner O; Kirilmaz A
    Turk Kardiyol Dern Ars; 2009 Jul; 37(5):364; author reply 365. PubMed ID: 19875919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.